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Abstract: Variable response and resistance to tamoxifen treatment in breast cancer patients remains a major clinical problem. To 
  determine whether genes and biological pathways containing SNPs associated with risk for breast cancer are dysregulated in response 
to tamoxifen treatment, we performed analysis combining information from 43 genome-wide association studies with gene expression 
data from 298 ER+ breast cancer patients treated with tamoxifen and 125 ER+ controls. We identified 95 genes which distinguished 
tamoxifen treated patients from controls. Additionally, we identified 54 genes which stratified tamoxifen treated patients into two 
distinct groups. We identified biological pathways containing SNPs associated with risk for breast cancer, which were dysregulated in 
response to tamoxifen treatment. Key pathways identified included the apoptosis, P53, NFkB, DNA repair and cell cycle pathways. 
Combining GWAS with transcription profiling provides a unified approach for associating GWAS findings with response to drug treat-
ment and identification of potential drug targets.
Keywords: tamoxifen genome-wide association studies gene expressionhicks et al
48  Breast Cancer: Basic and Clinical Research 2012:6
Introduction
Despite advances in diagnosis and treatment, breast 
cancer remains a major public health problem and 
a  major  cause  of  death  for  women  worldwide.1 
  Excluding cancers of the skin, breast cancer is the 
most common cancer among women, accounting for 
nearly 1 in 4 cancers diagnosed in US women.1 In 
2009, an estimated 192,370 new cases of invasive 
breast cancer were diagnosed among women, as well 
as an estimated 62,280 additional cases of in situ breast 
cancer.1 Out of all breast cancer patients diagnosed in 
2009, an estimated 40,170 died from the   disease, mak-
ing it the second most deadly cancer among women 
after lung cancer.1 While treatment and control remain 
the top priorities, identification of molecular markers 
which are dysregulated in response to treatment is 
an important long-term goal for the development of 
more effective therapeutic strategies.
Approximately 70% of the known breast tumors 
express estrogen receptor α (ER).2 For women whose 
tumors are endocrine sensitive, as indicated by the 
expression of the ER, tamoxifen represents the most 
important therapeutic modality.3 Large clinical trials, 
such as the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) trials B-14 and B-20 have 
demonstrated the benefit of   tamoxifen treatment in 
women who have node-negative, estrogen-  receptor-
positive  breast  cancer.4,5  However,  response  to 
  tamoxifen treatment varies considerably among breast 
cancer patients. In the advanced setting,   approximately 
50% of the patients with ER positive breast tumors 
will not respond to endocrine treatment, and among 
those who respond some tend to relapse.6
Evidence  from  the  published  literature  using 
transcription profiling has shown that response and 
resistance  to  tamoxifen  treatment  are  both  under 
polygenic  control.7–9  Nevertheless,  despite  this 
  recognition,  the  molecular  mechanisms  underly-
ing  variable  response  and  resistance  to  tamoxifen 
treatment  are  poorly    understood.  Recent  advances 
in  high-throughput  genotyping  and  a  reduction  in 
genotyping costs have made possible identification 
of genetic variants (SNPs) associated with risk for 
breast cancer using genome-wide association studies 
(GWAS).10,11   However, although these genetic vari-
ants are providing variable clues about the genetic 
susceptibility landscape of breast cancer, there remain 
many   challenges to   overcome in order to understand 
fully  the    contribution  of  genetic  polymorphisms 
to response and resistance to drug treatment and to 
translate this new knowledge into clinical practice.
Here  we  use  a  gene-centric  approach  to  dem-
onstrate  the  power  of  combining  GWAS  informa-
tion with gene expression data to identify potential 
  candidate genes and biological pathways containing 
SNPs associated with risk for breast cancer, which 
are dysregulated in response to tamoxifen treatment. 
The objectives of this study were three-fold: (1) to 
investigate whether genes containing SNPs associ-
ated with risk for breast cancer are dysregulated in 
response to Tamoxifen treatment, (2) Within patients 
treated with tamoxifen identify a molecular signature 
of genes which stratify patients into distinct groups 
on the basis of response to tamoxifen treatment, and 
(3) to identify biological pathways containing SNPs 
associated with risk for breast cancer, that are dys-
regulated  in  response  to  tamoxifen  treatment.  Our 
method focuses on the genes and biological pathways 
rather than individual SNPs. This holistic approach is 
aimed at providing insights about the broader biologi-
cal context in which the SNPs associated with risk for 
breast cancer operate.
Material and Methods
Source of SnP data
Short of being able to get raw GWAS data to per-
form traditional single-SNP GWAS analysis to iden-
tify SNPs associated with risk for breast cancer, we 
obtained SNP data by mining data from 43 published 
GWAS reports and supporting websites containing 
supplementary data reported through June 2011 using 
PubMed  searches.  The  studies  evaluated  involved 
over 250,000 cases and over 250,000 controls. As 
an  inclusion  criteria,  only  studies  with  samples 
of .500 samples were considered. The methods of 
SNP  data  collection  including  sources,  along  with 
SNP annotation and gene name validation have been 
fully described in detail and reported in our previous 
studies.10,11
To address publication bias, we catalogued all the 
SNPs  that  showed  significant  (P  ,  0.05)  associa-
tion with risk for breast cancer. This low threshold 
is based on the rationale that breast cancer is a poly-
genic disease involving many genes interacting with 
each other, with each gene having only a small effect 
on the observed phenotype. Therefore, restricting the Response to tamoxifen treatment
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analysis to only those genes containing SNPs with the 
smallest P-values (P , 10−5) could potentially miss 
important biological pathways modulating response 
to  drug  treatment.  Conversely,  use  of  functionally 
related  genes  containing  SNPs  with  the  smallest 
P-values and those containing SNPs with moderate 
P-values (P = 10−5∼P , 0.05) together could provide 
new insights about how the two sets of genes work in 
concert in response to drug treatment or to produce a 
particular breast cancer phenotype.
The SNP, IDs (rs-ID), locations and gene names 
were verified using the dbSNP database using chro-
mosome report build 37.1 and the Human Genome 
Nomenclature  (HGNC)  database.  SNPs  were 
matched with gene names using SNP IDs (rs-IDs) 
information contained in the dbSNP database. The 
analysis yielded a total 500 genetic variants (SNPs), 
of  which  113  mapped  to  intergenic  regions  and 
were not included in further analysis. The remain-
der 387 SNPs mapped to 110 genes. These genetic 
variants and genes formed the basis of our analysis 
to   identify the molecular signatures and biological 
pathways  dysregulated  in  response  to  tamoxifen 
treatment,  and  to  identify  novel  genes  which  act 
in concert with genes containing SNPs associated 
with risk for breast cancer. As noted, a complete 
catalogue of genetic variants and genes along with 
references has been reported elsewhere in our pre-
vious studies.10,11
Source of gene expression data
We used publicly available gene expression data. The 
data consisted of 298 ER+ breast cancer patients uni-
formly treated with Tamoxifen and 125 ER+ breast can-
cer patients (controls) not treated with   Tamoxifen. All 
the data was derived from the   Caucasian   population. 
The 298 samples were derived from fresh   frozen tissue 
obtained from ER+ invasive breast   cancer patients that 
were profiled at the Institut Jules Bordet in France.8 
The 125 ER+ were breast cancer patients with pri-
mary operable invasive breast   cancer, whose frozen 
tumor specimens were archived at the John Radcliffe 
  Hospital (Oxford, UK) and the   Uppsala University 
  Hospital  (Uppsala,  Sweden).12  No  patient  from  the 
125 ER+ had received any adjuvant systematic therapy. 
The methods of sample preparation and data collection 
have been fully described by the data originators.8,12 
All samples were assessed for global gene expression 
profiles  using  the  Affymetrix    platform  on  U133A 
Human Chips. The data from these samples consisted 
of the raw probe-level hybridization intensities, which 
were downloaded from the NCBI’s Gene Expression 
Omnibus  (GEO)  database  http://www.ncbi.nlm.nih.
gov/geo/  under  accession  numbers:  GSE17705  and 
GSE2990, respectively.
In each of the data sets described above, entries in 
the data matrix were expression values generated by 
Affymetrix’s Microarray Analysis Suite 5.0 (MAS5) 
statistical  algorithm.13  Following  normalization 
and scaling, MAS5 signal values were summarized 
by Turkey’s biweight estimation of the probe level 
intensities within each probe set. This was followed 
by a global normalization (linear scaling) to give all 
chips the same average intensity. These procedures 
yield robust weighted means called average-scaled 
differences that are proportional to the amount of a 
particular RNA transcript present in the sample after 
background correction, which we used as the input 
in this analysis. All the data was already log trans-
formed (log2). Spiked control genes were removed 
during pre-processing of the data.
Data analysis
Our analysis strategy follows a gene-centric approach. 
Under this approach we assumed that the genes and 
pathways containing SNPs are the units of association. 
This holistic approach has several attractive features: 
(i) by focusing on the genes and biological pathways 
instead of individual SNPs, it allows us to make infer-
ence about the broader biological context in which 
the genetic variants operate. (ii) It allowed us to con-
sider the joint effects of all the SNPs including those 
with small effects and potential rare variants as well 
as cis regulatory elements which may be impacted by 
SNPs mapped to the genes under study. (iii) Through 
co-expression analysis and pathway prediction, this 
approach allows identification of other genes which 
are correlated or functionally related with those con-
taining SNPs associated with risk for breast cancer. 
Such genes could not be identified using traditional 
single-SNP GWAS analysis. Therefore, it is an   optimal 
analysis strategy. For genes containing multiple SNPs 
and  those  containing  SNPs  replicated  in  multiple 
independent studies, we computed their overall effect 
size (P-value) using the procedures described in our 
previous studies.10,11hicks et al
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As a first step, we randomized and partitioned gene 
expression  data  into  two  independent  data  sets  of 
almost equal sizes, the test set and the validation set. 
The rationale for partitioning the data set was to deter-
mine the reliability and reproducibility of the results 
by repeating the analysis using the validation set. The 
test set contained 149 ER+ breast cancer patients uni-
formly treated with Tamoxifen and 62 ER+ controls. 
The validation set included 149 ER+ breast cancer 
patients treated with Tamoxifen and 63 ER+ controls. 
The data was normalized using a lowess normaliza-
tion method, a widely used nonlinear correction tech-
nique which allowed us to account for any potential 
extreme outliers.14
We  performed  a  combination  of  analysis  strat-
egies on gene expression data. In the first strategy, 
supervised analysis, we compared gene expression 
data between tamoxifen treated patients and controls, 
using a t-test, performed on the test and validation 
data sets. The goal was to identify significantly differ-
entially expressed genes containing SNPs associated 
with risk for breast cancer, that are dysregulated in 
response to drug treatment. We used a false discovery 
rate procedure15 to correct for multiple testing. Genes 
were ranked based on estimates of P-values and SNP-
containing genes which were significantly (P , 0.05) 
differentially  expressed  between  tamoxifen  treated 
and controls were selected.
In the second step, unsupervised analysis, we per-
formed pattern recognition analysis using hierarchi-
cal clustering based on complete linkage method and 
correlation distance. The goal was to identify SNP-
containing genes with similar patterns of expression 
profiles  among  genes  exhibiting  significant  differ-
ences in expression between cases and controls. In 
addition, this analysis was carried out to determine 
whether genes containing SNPs with small P-values 
and SNPs replicated in multiple independent studies 
interact with genes containing SNPs with moderate 
P-values. Generally, SNPs with moderate P-values 
are  “often  considered  not  genome-wide  significant 
in  traditional  GWAS  analysis”.  Prior  to  perform-
ing hierarchical clustering, the data was normalized, 
standardized and centered using the methods devel-
oped by Eisen et al.16 This analysis was performed 
on a set of genes which provided good evidence of 
distinguishing  breast  cancer  patients  treated  with 
  tamoxifen from controls.
In  the  third  step,  we  performed  unsupervised 
  followed by supervised analysis within the 298 breast 
cancer patients treated with tamoxifen. The objective 
was to identify a signature of genes which exhib-
ited  significant  differences  in  expression  profiles 
in  response  to  tamoxifen  treatment  within  treated 
patients.  To  achieve  this  objective,  we  used  gene 
expression data on the set of significantly differentially 
expressed genes identified using the test and valida-
tion sets. Supervised analysis was performed using 
Pomello II.17 Unsupervised and correlation   analysis 
were  performed  using  GenePattern    software.18  We 
used  the  Pearson  correlation    coefficient  to  assess 
whether genes containing SNPs with small P-values 
and  genes  containing  SNPs  replicated  in  multiple 
independent studies are co-expressed with genes con-
taining SNPs with moderate P-values. The correla-
tion coefficient between pairs of genes was estimated 
using the SAS System.19
In the fourth step, we combined data on genes con-
taining SNPs with the most significant P-values and 
those replicated in multiple independent studies (see 
Table  1  and  Table  2  in  this  report)  with  data  on 
19 genes experimentally confirmed to be predictive 
of resistance to tamoxifen treatment. The 19 genes 
experimentally confirmed to be tamoxifen resistant 
included  the  genes,  RAD21,  BAP1,  NAE1,  MYC, 
TNFAIP3,  CLLP,  CEACAM6,  PTEN,  RARG,  NF1, 
PAX2, NIPBL, CCND1, UAB3, SMC3, PAK1, ERBB2, 
NSD1, GPRC5D. The genes were identified by min-
ing the literature on tamoxifen resistance focusing 
only on reports which have experimental conforma-
tion.9,20–25 We performed supervised analysis, correla-
tion analysis and pattern recognition analysis on the 
combined data set. The objectives of these analyses 
were two-fold: (1) to determine whether genes con-
taining SNPs and genes resistant to tamoxifen are 
predictive of response to tamoxifen and to identify 
genes that are resistant to tamoxifen treatment, (2) 
To determine whether genes containing SNPs are co-
regulated and have similar patterns of expression pro-
files with experimentally confirmed genes predictive 
of resistance to tamoxifen treatment.
To determine how genes containing SNPs and genes 
resistant to tamoxifen treatment affect the   survival out-
come, we compared the expression   values of the com-
bined set of genes between 71 breast   cancer patients 
who relapsed and 227 breast cancer patients who did Response to tamoxifen treatment
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not  relapse.  Significantly    differentially  expressed 
genes were then correlated with the 19 genes that 
are resistant to tamoxifen   treatment. The goal was to 
determine which of the genes containing SNPs could 
be potential predictors of outcome, and whether they 
correlate  or  are  co-expressed  with  known  predic-
tors of tamoxin resistance. It is worth noting that this 
analysis was carried out in the absence of other vari-
ables such as age, tumor grade, as such data was not 
  available. Data analysis in the fourth step was per-
formed  using  the  GenePattern    Software  Package18 
and the SAS Software Package.19
Finally,  we  performed  pathway  prediction  and 
network visualization using the Ingenuity System26 to 
determine whether genes containing SNPs associated 
with risk for breast cancer, interact with each other in 
biological pathways. The goal was to identify biologi-
cal pathways and gene regulatory networks containing 
SNPs, which are dysregulated in response to tamox-
ifen treatment. Therefore, for pathway prediction and 
network modeling, the inputs were the genes contain-
ing SNPs, which were dysregulated in response to 
tamoxifen  treatment.  Gene  expression  values  were 
included in the input to identify up and down regu-
lated genes in the pathways. The same analysis was 
applied to a set of genes which stratified tamoxifen 
treated  patients.  Validation  of  predicted  pathways 
and identification of other downstream target genes 
was  achieved  using  the  global  pathway  prediction 
and network modeling module built in the   Ingenuity 
  System. This global approach allowed identification 
of  other  functionally  related  genes  and  biological 
pathways, which could not be identified using tradi-
tional single-SNP GWAS analysis. Functional rela-
tionship among SNP-containing genes and with other 
genes was assessed using gene ontology (GO) infor-
mation incorporated in the ingenuity system and the 
GO database.27 The overall effect size for the SNPs in 
the pathways (defined as the average P-value of SNPs 
within a pathway) was computed using the procedure 
reported in our earlier study.11
Results
Identifying  genetic  variants  that  increase  suscepti-
bility to breast cancer has been the primary aim of 
genome-wide  association  studies  with  application 
to breast cancer and other common human   diseases. 
However, identification of genetic variants by means 
of such studies provides limited insights about the 
  biological  context  in  which  genetic  variants  oper-
ate.  This  knowledge  gap  is  hampering  translation 
of  genomic  discoveries  into  clinical  practice  to 
guide patient treatment. Although in some cases this 
  knowledge immediately illuminates a path towards 
development  of  therapeutic  strategies,28,29  to  date, 
there is no information regarding the use of GWAS 
information to guide drug treatment in breast can-
cer patients. In this study, we have used the power 
of integrative genomic and bioinformatics analysis 
combing GWAS information from 43 genome-wide 
association  studies  and  gene  expression  data  on 
298 ER+ breast cancer patients uniformly treated with 
tamoxifen and 125 ER+ untreated controls to deter-
mine whether genes and biological pathways contain-
ing SNPs associated with risk for breast cancer are 
dysregulated in response to tamoxifen treatment. The 
results of this analysis are presented below.
Response to TAM treatment
One of the primary objectives of this study was to 
investigate whether genes containing SNPs associ-
ated with risk for breast cancer are dysregulated in 
response to Tamoxifen treatment. We hypothesized 
that genes containing SNPs associated with risk for 
breast cancer significantly differ in their expression 
profiles between ER+ breast cancer patients treated 
with tamoxifen and ER+ control patients not treated 
with tamoxifen. We tested this hypothesis by compar-
ing the expression of genes containing SNPs associ-
ated with risk for breast cancer between tamoxifen 
treated and untreated patients using the test and vali-
dation  data  sets.  The  results  showing  significantly 
(P  ,  0.05)  differentially  expressed  genes  distin-
guishing tamoxifen treated from untreated ER+ con-
trol breast cancer patients are presented in Figures 1 
and 2 for the test and validation sets,   respectively. 
Out of the 110 genes containing SNPs associated with 
risk for breast cancer tested, we identified 101 sig-
nificantly (P , 0.05) differentially expressed genes, 
which clearly distinguished tamoxifen treated patients 
from controls, in the test set (Fig. 1). These genes 
were also identified and validated in the validation 
set which produced 97 significantly (P , 0.05) dif-
ferentially  expressed  genes  distinguishing  the  two 
groups (Fig. 2). After ranking the genes in the test and 
validation sets, we identified a signature of 95 highly hicks et al
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Figure 1. Predictive power of the 92 significantly differentially genes 
identified by comparing mean gene expression values in the 149 ER+ 
breast cancer patients uniformly treated with tamoxifen and 62 eR+ 
control breast cancer patients.
note: expression values are based on a log scale (log2).
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Figure 2. Predictive power of the 93 significantly differentially genes 
identified by comparing mean gene expression values in the 149 ER+ 
breast cancer patients uniformly treated with tamoxifen and 63 eR+ 
control breast cancer patients.
note: expression values are based on a log scale (log2).
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Figure 3. Distribution of genes for the 95 gene signatures identified using 
the test and validation data sets.
notes: The number 90 genes in the intersection set indicate the most 
highly significant genes which overlapped  between the test and vali-
dation data sets. All genes were selected using the same threshold of 
P , 0.000001 in the test and validation set. The numbers 2 and 3 repre-
sent the significantly differentially expressed genes at P , 0.000001 only 
in the test set and only validation set, respectively.
  significant (P , 0.000001) differentially expressed 
genes  (FDR  =  0),  which  distinguished  tamoxifen 
treated from untreated breast cancer patients (Fig. 3). 
The results confirmed our hypothesis that genes con-
taining SNPs associated with risk for breast cancer 
are dyregulated in response to tamoxifen treatment.
As expected from the 95 gene signature identi-
fied, 90 genes overlapped between the test and vali-
dation  sets  (Fig.  3)  confirming  the  reproducibility 
of the results. Out of the 95 gene signature identi-
fied, 13 genes contained SNPs with small P-values 
(P , 10−5) (Table 1), whereas 19 genes contained 
SNPs  replicated  in  multiple  independent  studies 
(Table  2).  The  rest  of  significantly  differentially 
expressed  genes  contained  SNPs  with  moderate 
P-values (P = 10−4∼P , 10−2). This finding was of 
particular  interest,  given  that  SNPs  with  moderate 
P-values are often considered to be noise and thus of 
less value in traditional single-SNP GWAS analysis. 
Estimates of P-values and FDR in the test and valida-
tion data sets for all the 110 genes derived from gene 
expression  data  comparing  breast  cancer  patients 
treated with tamoxifen to controls are presented in 
Table A, in the appendix, provided as supplementary 
data. The 95 gene signature identified in this study 
indicates that genes containing SNPs associated with 
risk for breast cancer could be potential predictors of 
response to tamoxifen treatment.
To  determine  whether  genes  containing  SNPs 
associated with risk for breast, which distinguished 
tamoxifen  treated  from  untreated  ER+  breast  can-
cer  patients  exhibit  similar  patterns  of  expression 
profiles, we performed unsupervised analysis using 
hierarchical clustering. We hypothesized that genes 
containing SNPs associated with risk for breast can-
cer are functionally related and are likely to exhibit 
similar  patterns  of  expression  profiles  in  response 
to tamoxifen treatment. Figure 4 shows patterns of 
gene expression profiles for the top 92 significantly 
(P , 0.00001) differentially expressed up and down 
regulated  genes  (FDR  =  0),  which  distinguished 
tamoxifen treated breast cancer patients from controls 
for the test set. Patterns of gene expression profiles 
for the top 93 significantly (P , 0.00001) differen-
tially expressed genes (FDR = 0) identified in the 
validation set are presented in Figure 5. We   identified Response to tamoxifen treatment
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Table 1. List of genes and SnPs with the smallest P-values (large effect size) associated with risk for breast cancer, and 
estimates of P-values for the SnP-containing genes which responded to tamoxifen treatment, in the test and validation   
data sets.
Gene name snp_ID estimated  
GWAs-P-value
estimated P-value  
in test set
estimated P-value   
in validation set
SLC4A7 rs4973768 4 × 10−23 0.04 1.00e-05
CASP8 rs1045485 1.1 × 10−5 5.00e-06 5.00e-06
TgFB1 rs1800470 2.8 × 10−5 5.00e-06 5.00e-06
eSR1 rs3020314 8.4 × 10−5 5.00e-06 5.00e-06
LSP1 rs3817198 3 × 10−9 1.50e-05 5.00e-06
TOX3 rs8051542 1.0 × 10−36 5.00e-06 5.00e-06
TOX3 rs12443621 2 × 10−19 5.00e-06 5.00e-06
RnF146 rs2180341 2.9 × 10−8 5.00e-06 5.00e-06
eChDC1 rs6569480 6.1 × 10−8 5.00e-06 5.00e-06
eChDC1 rs7776136 6.6 × 10−8 5.00e-06 5.00e-06
ABCC4 rs1926657 1.9 × 10−6 5.00e-06 5.00e-06
BTnL8 rs7711970 8.4 × 10−5 5.00e-06 5.00e-06
COLiA1 rs2075555 8.3 × 10−8 5.00e-06 5.00e-06
gRiK1 rs458685 6.0 × 10−5 1.00e-05 5.00e-06
RAD51L1 rs999737 1.74 × 10−7 5.00e-06 5.00e-06
Table 2. List of genes and SnPs associated with risk for breast cancer, replicated in multiple independent studies, and 
estimates of P-values for the SnP-containing genes which responded to tamoxifen treatment, in the test and validation data 
sets.
Gene name snp_ID number of  
replication
Range of estimated  
GWAs-P-values
estimated P-value  
in test set
estimated P-value   
in validation set
ADh1B rs1042026 3 0.02–0.03 5.00e-06 5.00e-06
CASP8 rs1045485 2 0.02–1.1 × 10−7 5.00e-06 5.00e-06
CDKn1B rs34330 2 0.01–0.01 5.00e-06 5.00e-06
CDKn2A rs3731239 2 0.01–0.001 5.00e-06 5.00e-06
COMT rs4818 2 0.05–0.02 5.00e-06 5.00e-06
ehMT1 rs4634736 2 0.02–0.02 5.00e-06 5.00e-06
iCAM5 rs1056538 2 0.05–0.001 5.00e-06 5.00e-06
igBP3 rs2854744 5 0.03–0.05 5.00e-06 5.00e-06
LSP1 rs3817198 6 0.05–3 × 10−9 1.50e-05 5.00e-06
MAP3K1 rs889312 3 0.05–0.05 5.00e-06 5.00e-06
PgR rs1042838 2 0.02–0.05 0.007 0.0006
RB1 rs198580 2 0.02–0.02 5.00e-06 5.00e-06
ReLn rs17157903 2 0.05–0.0006 0.0006 1.00e-05
SOD2 rs4880 2 0.01–0.05 5.00e-06 5.00e-06
SORBS1 rs10450393 2 0.01–0.03 4.50e-05 1.50e-05
TgFB1 rs1800470 4 0.05–2.8 × 10−5 5.00e-06 5.00e-06
eSR1 rs3020314 2 8.4 × 10−5–8 × 10−5 5.00e-06 5.00e-06
SLC4A7 rs4973768 3 0.05–4 × 10−23 0.04 1.00e-05
TOX3 rs8051542 2 0.05–1.0 × 10−36 5.00e-06 5.00e-06
clusters  of  co-expressed  up  and  down    regulated 
genes  with  similar  patterns  of  expression  profiles 
(Figs. 4 and 5). This confirms our hypothesis that 
genes containing SNPs associated with risk for breast 
cancer are co-regulated and functionally related. As 
expected, patterns of expression profiles in the test 
set (Fig. 4) and validation set (Fig. 5) were identical. 
Interestingly, genes containing SNPs with the small-
est P-values, and genes containing SNPs replicated in 
multiple independent studies were co-expressed and 
exhibited similar patterns of expression with genes 
containing SNPs with moderate P-values. This result hicks et al
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Figure 4. Patterns of gene expression for the 92 significantly (P  10−6) differentially expressed genes containing SnPs associated with risk for breasted 
cancer, distinguishing the 149 tamoxifen treated (right) patients from 62 cancer-free controls (left) in the test set.
note: genes are shown in rows and breast cancer patients in columns. Red color indicates upregulation and blue color indicated down regulation.
Figure 5. Patterns of gene expression for the 93 significantly (P  10−6) differentially expressed genes containing SnPs associated with risk for breasted 
cancer, distinguishing the 149 tamoxifen treated patients (right) from 63 cancer-free controls (left) in the validation set. 
note: genes are shown in rows and breast   cancer patients in columns. Red color indicates upregulation and blue color indicate down regulation.
confirms our hypothesis that genes containing SNPs 
with small P-values and genes containing SNPs repli-
cated in multiple independent studies are likely to act 
in concert with genes containing SNPs with moderate 
P-values in response to drug treatment.
To determine the functional relationship of  identi-
fied genes we used the gene ontology (GO) informa-
tion.21 GO analysis allows characterization of genes 
according to the GO nomenclature. The GO consortium 
has developed three separate ontologies-molecular or 
physiological function, biological process and cellular 
component to describe the attributes of gene products. 
Molecular function defines what a gene product does 
at the biochemical level without specifying where or 
when the activity occurs; biological process describes 
the  contribution  of  a  gene  product  to  a  biological 
objective; while cellular component refers to where 
in the cell a gene product functions. Here we char-
acterized the genes according to all three GO catego-
ries in which the genes containing SNPs   associated Response to tamoxifen treatment
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with risk for breast cancer are involved. The results of 
GO classification are presented in Table A for all the 
110 genes examined, presented as supplementary data. 
GO information revealed that genes containing SNPs 
associated with risk for breast cancer are function-
ally related, and are involved in the same biological 
processes. Interestingly, genes containing SNPs with 
small P-values were found to be functionally related 
with those containing SNPs with moderate P-values, 
suggesting that the two sets of genes could be acting 
in concert in response to drug treatment. Importantly, 
genes containing SNPs with large and small P-values 
were found to be interacting with genes containing 
SNPs replicated in multiple independent studies. This 
is a significant finding given that replication is often 
difficult to achieve in traditional single-SNP GWAS 
analysis. These results show that high-throughput SNP 
mapping combined with transcription profiling data 
could lead to identification of potential drug targets.
In both the test and validation sets, we observed 
variable  response  to  tamoxifen  treatment  among 
patients, confirming our original hypothesis that indi-
vidual patients respond differently to tamoxifen treat-
ment. Part of the observed differences in individual 
patient’s  response  to  tamoxifen  treatment  can  be 
explained by genetic and phenotypic   heterogeneity, 
although  other  factors  such  as  age,  tumor  grade, 
could not be ruled out. This clinical information was 
not available in the data sets used and therefore we 
did not consider them in our analysis. However, the 
observed variation in response to Tamoxifen treatment 
is consistent with literature reports.3 Importantly, the 
results of this study show that response to tamoxifen 
treatment is under polygenic control and that genes 
containing SNPs associated with risk for breast can-
cer are likely to play an important role in endocrine 
therapy. This finding provides insights about the func-
tional bridges between GWAS findings and response 
to drug treatment, and suggests that genes containing 
SNPs associated with risk for breast cancer could be 
potential drug targets.
Stratifying patients on the basis  
of response to tamoxifen treatment
One  of  the  major  challenges  in  endocrine  therapy 
and in particular tamoxifen treatment is variability 
and resistance in breast cancer patients’ response to 
treatment.  Therefore,  understanding  the    molecular 
  mechanisms  underlying  variable  response  and 
  resistance  to  drug  treatment  is  critical.  Therefore, 
our second objective in this study was to investigate 
whether within the 298 breast cancer patients treated 
with tamoxifen we could identify a molecular signa-
ture of SNP-containing genes, which stratified patients 
on the basis of variability and differences in response 
to tamoxifen treatment. The underlying hypothesis 
supported by evidence from the literature is that in the 
advanced setting, approximately 50% of the patients 
with ER+ breast tumors will not respond to endocrine 
treatment,6 and many who do initially respond, sub-
sequently relapse due to the acquisition of endocrine 
resistance.30 We reasoned that identifying a signature 
of  genes  discriminating  patients  within    tamoxifen 
treated  patients  could  provide  insights  about  the 
potential molecular mechanisms underlying variable 
response and resistance to tamoxifen treatment. Such 
outcome could have a significant clinical impact by 
making it possible to stratify breast cancer patients 
according to various tailored treatments by identify-
ing good responders from poor responders.
To  formally  test  this  hypothesis,  we  performed 
unsupervised followed by supervised analysis of gene 
expression data within the 298 breast cancer patients 
uniformly treated with tamoxifen. This analysis was 
performed  on  the  95  genes,  which  were  dysregu-
lated in response to tamoxifen treatment. From the 
95 genes tested, we identified 76 genes which exhib-
ited significant (P , 0.05) differences in expression 
profiles. After ranking the genes on the basis of esti-
mated P-values, we identified a signature of 54 highly 
significantly (P , 0.000001) differentially expressed 
genes (FDR = 0), which clearly distinguished patients 
treated with tamoxifen into two distinct groups (Fig. 6). 
The 54 gene signature included genes involved in 
estrogen action, apoptosis, extracellular matrix and 
immune response. Within the 54 gene signature, the 
genes  DCLREIC,  WWOX,  RPA2,  BLM,  DMBT1, 
PPP2R2B, TRIM45, IGF1R, MMP8, ICAM1, RELN 
were up regulated, whereas the genes SKAP2, APEX1, 
CDC37 L1, C1ORF38, MGMT, CASP8, RB1, TGFB1, 
XRCC5, MSH2, CSFT1, RPA, MSH6, EHMT2, XPA, 
PRKDC and ERCC5 were down regulated (Fig. 6). 
The 54 gene signature included 10 genes, CASP8, 
TGFB1,  LSP1,  TOX3,  ECHDC1,  ABCC4,  BTNL8, 
COLIA1,  GRIK1  and  RAD51L1  containing  SNPs 
with small P-values; and 15 genes, ADH1B, CASP8, hicks et al
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CDKN1B,  CDKN2A,  LSP1,  MAP3K1,  PGR,  RB1, 
RELN, SOD2, SORBS1, TGFB1, ESR1, SLC4A7 and 
TOX3 containing SNPs replicated in multiple inde-
pendent studies. The remainder of the genes in the 
54  gene  signature  contained  SNPs  with  moderate 
P-values. A complete list of the 95 genes (including 
the 54 genes), and their estimates of P-values and 
false discovery rates based on the 298 patients treated 
with tamoxifen are presented in Table B, provided as 
supplementary material. Also presented in Table B is 
information on biological process, molecular func-
tion and cellular process in which the 95 genes are 
involved.
Overall, the results of the 54 gene signature confirm 
our hypothesis that genes containing SNPs associated 
with risk for breast cancer could discriminate patients 
treated with tamoxifen. This is an important finding 
in that these genes could be used to stratify patients 
into good and poor responders. Functional information 
using GO nomenclature revealed that the genes are 
functionally related (see Table B, supplementary data). 
Interestingly, co-expression analysis within the 54 gene 
signature revealed that, genes containing SNPs with 
small P-values and SNPs replicated in multiple inde-
pendent studies were co-expressed with genes contain-
ing SNPs with moderate P-values (Fig. 6).
Prediction of clinical outcome  
and resistance to tamoxifen treatment
One of the major challenges in endocrine therapy is 
resistance to tamoxifen treatment and how this affects 
patient  outcome.  Genetic  mechanisms  underlying 
resistance to tamoxifen treatment remain unknown. 
Therefore, our third objective in this study was to iden-
tify genes containing SNPs associated with risk for 
breast cancer that predictive resistance to tamoxifen 
  treatment  and  clinical  outcome.  We  reasoned  that 
genes containing SNPs associated with risk for breast 
cancer either by themselves or acting in concert with 
other resistant genes confer resistance to tamoxifen 
treatment and affect clinical outcome. To address this 
question, we performed supervised and unsupervised 
analysis combining data on 26 genes containing SNPs 
with the most significant P-values and those repli-
cated in multiple independent studies with data on 
19 genes experimentally confirmed to be predictive of 
resistance to tamoxifen treatment. The genes contain-
ing the most highly significant and replicated SNPs 
included:  SLC4A7,  CASP8,  TGFB1,  ESR1,  LSP1, 
TOX3, RNF146, ECHDC1, ABCC4, BTNL8, COLIA1, 
GRIK1,  RAD51L1,  ADH1B,  CDKN1B,  CDKN2A, 
COMT,  EHMT1,  ICAM5,  IGBP3,  MAP3K1,  PGR, 
RB1, RELN, SOD2, and SORBS1. (see Table 1 and 
Table 2 in this report). The genes resistant to tamox-
ifen treatment included (RAD21, BAP1, NAE1, MYC, 
TNFAIP3,  CLLP,  CEACAM6,  PTEN,  RARG,  NF1, 
PAX2, NIPBL, CCND1, UAB3, SMC3, PAK1, ERBB2, 
NSD1, GPRC5D). This approach allowed in silico 
analysis and validation.
Figure  7  shows  patterns  of  expression  for  the 
45 gene signature in treated and controls. Estimates of 
P-values derived from supervised analysis comparing 
tamoxifen treated with controls for the combined set 
of genes are presented in Table C provided as addi-
tional supplementary data. All the 45 genes were sig-
nificantly differentially expressed between tamoxifen 
treated and controls, suggesting that these genes are 
predictive of response to tamoxifen. Pattern recogni-
tion analysis revealed that genes containing SNPs and 
genes resistant to tamoxifen were co-expressed and 
had similar patterns of expression profiles (Fig. 7), 
confirming  our  hypothesis  that  genes  containing 
Figure 6. Patterns of gene expression for the top 54 significantly (P  10−6) differentially expressed genes containing SnPs associated with risk for 
breasted cancer, distinguishing poor responders from good reponders within the 298 tamoxifen treated patients. 
note: genes are shown in rows and breast cancer patients in columns. Red color indicates upregulation and blue color indicate down regulation.Response to tamoxifen treatment
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SNPs either alone or in concert with genes resistant 
to tamoxifen treatment confer resistance to tamoxifen. 
This indicates that genes containing SNPs could be 
potential therapeutic targets, although the specific role 
of  SNPs  warrants  further  investigation.  In  general, 
both tamoxifen resistant genes and genes containing 
SNPs associated with risk for breast cancer exhibited 
significant variation in expression in both tamoxifen 
treated patients and controls. The variability in pat-
terns of expression can be explained in part by the 
introduction of the 19 tamoxifen resistance genes in 
the   analysis. This analysis also demonstrates that use 
of GWAS information alone may miss other important 
genes that are predictive of clinical outcomes, notably, 
genes conferring resistance to tamoxifen treatment.
To  further  evaluate  the  association  between 
  tamoxifen  resistant  genes  and  genes  containing 
SNPs, we performed correlation analysis between the 
two sets of genes within the 298 patients treated with 
  tamoxifen. This analysis yielded significant correla-
tions between tamoxifen resistant genes and genes 
containing SNPs. Among the most significantly cor-
related or co-expressed genes included: BAP1* vs. 
SORBS1, r = −0.30; UBA3* vs. SORBS1, r = 0.4; 
PTEN*  vs.  SORBS1,  r  =  41;  UBA3*  vs.  CASP8, 
r = 0.25; PTEN* vs. ADH1B, r = 0.26; CASP8 vs. 
NF1*, r = −0.23; (* indicates resistant gene). The 
correlations  between  genes  containing  SNPs  and 
genes resistant to tamoxifen suggest that the two sets 
of genes likely act in concert to confer resistance or 
dysregulation to tamoxifen treatment.
To  determine  whether  genes  containing  SNPs 
could be predictive of clinical outcome we   compared 
gene expression values between the 71 breast cancer 
patients who relapsed and 227 breast cancer patients 
who did not relapse. We identified genes containing 
SNPs associated with risk for breast cancer which 
exhibited significant differences in expression between 
the breast cancer patients who relapsed and breast can-
cer patients who did not relapse. Among these genes 
included CASP8 (P , 0.0009), ADH1B (P , 0.0006), 
SORBS1 (P , 0.0008), PGR (P , 0.005), RNF146 
(P , 0.04); and genes resistant to tamoxifen RAD21 
(P , 0.04) and MYC (P , 0.05). These results tend to 
suggest that genes containing SNPs could be poten-
tial  predictors  of  clinical    outcome.  Co-expression 
analysis  of  genes  containing  SNPs  and  tamoxifen 
resistant genes revealed significant correlations sug-
gesting that the two sets of genes likely act in concert 
to affect clinical outcome.
Pathway analysis and network modeling
In a clinical setting, drug treatment may be aimed at 
targeting specific key biological pathways instead of 
individual genes, in order to be effective.   Identification 
of candidate biological pathways containing SNPs, 
which  are  dysregulated  in  response  to  drug  treat-
ment is critical. Therefore, our third objective in this 
study was to identify biological pathways containing 
SNPs mapped to genes dysregulated in response to 
tamoxifen treatment. We hypothesized that response 
to tamoxifen treatment is regulated by many genes 
interacting within biological pathways and gene reg-
ulatory  networks  containing  SNPs  associated  with 
risk for breast cancer. The results showing pathways 
and gene regulatory networks for the SNP-  containing 
genes  dysregulated  in  response  to    Tamoxifen 
  treatment are presented in Figures 8 and 9 for the 
Figure 7. Patterns of gene expression for the genes containing SnPs with smallest P-values and replicated in multiple independent studies with 19 genes 
resistant to tamoxifen treatment.
note: The left side indicates the 298 patients (in columns) treated with tamoxifen while the right side indicates the 125 patients not treated with tamoxifen 
herein referred to as controls. Mixed blue and red color in the same gene on the left indicates resistance in some patients. The red color indicates up 
regulation while the blue indicates down regulation. Analysis based on original raw data.hicks et al
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Figure 8. Network1 of the 95 gene signature. Pathways and gene regulatory networks for the 95 genes that exhibited significant differential expression.
note: genes mapped to legend symbols in red contain SnPs and are upregulated. genes mapped to legend symbols in green contain SnPs and are down 
regulated. All other genes are predicted genes no reported in gWAS studies. Prediction based on genes associated with response to tamoxifen treatment.
95 gene signature. Also presented in the pathways 
are  the  color  codes  red  and  green  indicating  the 
direction of change up and down regulation, respec-
tively, as assessed by gene expression. We identified 
key biological pathways dysregulated in response to 
tamoxifen treatment, including the Estrogen receptor, 
apoptosis, DNA replication, DNA missmatch repair, 
DNA repair, cell cycle, NFKB, Mapkinase, and P53 
pathways. Within the identified pathways, the genes 
COL1A1,  RELN,  SOD2,  RPA2,  MCC,  DCLRE1C, 
DMBT1, ESR1, WWOX, PPP2R2B, IGF1R, FANCA, 
MMP8, and ICAM1 were upregulated; whereas the 
genes  ERBB2,  RB1,  GRIK1,  CDKN1B,  TGFB1, 
CASP8,  MAP3K1,  XRCC5,  XRCC1,  RPA1,  GPX4, 
CHEK1,  XPA,  ERCC5,  CSTF1,  EHMT2,  MSH2, 
MSH3, C4ORF38, APEX1, SKAP2, CDC37L1, MSH6, 
and ALP1 were down regulated (Figs. 8 and 9). The 
pathways included genes involved in DNA replica-
tion, recombination, DNA repair, apoptosis, cell mor-
phology, cell growth and proliferation. The identified 
pathways  and  gene  regulatory  networks  included 
genes that are upregulated ESR1, COL1A1, IGFBP3, 
PPP2R2B;  and  down  regulated  CASP8,  GRIK1, 
MAP3K1, TGFB1 genes containing SNPs with small 
P-values (P , 10−5) (Figs. 8 and 9). Also identified in 
the pathways and gene regulatory networks were the 
genes  ESR1,  TGFB1,  CASP8,  IGFBP3,  CDKN1B, 
RB1 and MAP3K1 containing SNPs replicated in mul-
tiple independent studies. With the exception of ESR1 
which was up regulated, the rest of the genes contain-
ing SNPs associated with risk for breast  cancer were 
down  regulated  (Fig.  8).  Interestingly,  genes  con-
taining SNPs with the smallest P-values and genes 
containing SNPs replicated in multiple independent 
studies were found to interact with each other and 
with genes containing SNPs with moderate P-values. 
This result demonstrates that genes containing SNPs 
with small P-values and SNPs replicated in multiple 
independent studies are coordinately regulated with 
those containing SNPs with moderate P-values, in 
response  to  drug  treatment.  Importantly,  pathway 
prediction  and  network    modeling  also  identified Response to tamoxifen treatment
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Figure 9. network 2 of the 95 gene signature.
note: Pathways and gene regulatory networks for the 95 genes that exhibited significant differential expression. Genes mapped to legend symbols in 
red contain SnPs and are upregulated. genes mapped to legend symbols in green contain SnPs and are down regulated. All other genes are predicted 
genes no reported in gWAS studies. Prediction based on genes associated with response to tamoxifen treatment.
other genes that are functionally related and interact 
with genes containing SNPs associated with risk for 
breast cancer. Notably among these genes included 
genes  involved  in  the  NFKB  complex, TNF  com-
plex, FNG complex, NR3C1 complex, the immune 
system, and P53 pathway (Figs. 8 and 9). The results 
confirm our hypothesis that integrative analysis com-
bining  GWAS  information  with  gene  expression 
data provides a unified approach to identifying other 
genes which could not be identified using traditional 
single-SNP GWAS alone. The identification of mul-
tiple  biological  pathways  dysregulated  in  response 
to tamoxifen treatment suggests that global pathway 
crosstalk may be involved in regulating response to 
tamoxifen treatment.
To determine whether genes in the 54 gene sig-
nature interact with each other in pathways and gene 
regulatory networks, and to identify other genes which 
may interact with these genes, we performed pathway 
prediction and network modeling.   Figure 10 shows 
the pathways and gene interaction networks obtained 
from global pathway prediction and network modeling 
using the 54 gene signature. We identified multiple bio-
logical pathways including the apoptosis, P53, DNA 
repair, cell cycle and the NFkB pathways. Within the 
identified pathways and gene regulated networks were 
seventeen down regulated genes RPA, CSTF1, MSH2, 
RB1, XRCC5, CASP8, SKAP2, APEX1, CDC37L1, 
C1ORF38, TGFB1, MGMT, EHMT2, ERCC5, XPA, 
MSH6; and ten up regulated genes TRIM45, IGF1R, 
MMP8,  ICAM1,  RELN,  DMBT1,  PPP2R2B,  DCL-
RE1C, WWOX, BLM and RPA2. Among the identi-
fied genes were genes involved in DNA replication, 
recombination, DNA repair, cell death, cell morphol-
ogy, cellular development, and cellular function and 
maintenance. In addition, we identified other genes hicks et al
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which interact with genes containing SNPs associated 
risk for breast cancer, which have not been reported in 
GWAS.   Considerable variation in response to tamox-
ifen treatment was observed, which is consistent with 
previous reports involving transcription profiling.8
Consistent with our analysis, a wealth of informa-
tion about the potential clinical applications of the 
genes and biological pathway identified in this study 
exist. Estrogen is a pivotal regulator of cell prolif-
eration in breast cancer. Therefore, endocrine thera-
pies targeting the Estrogen receptor pathways such 
as tamoxifen could be effective molecular markers. 
Although the primary action of tamoxifen is believed 
to  be  through  inhibition  of  estrogen  receptor,  our 
research  shows  that  additional  non  ER  mediated 
molecular mechanisms exist, including the modula-
tion of the signaling proteins PKC, TGFB1, CASP8, 
NFkB  and  Map3K1,  which  play  a  critical  role  in 
TAM-induced apoptosis. For example, there are at 
least eleven isoforms of PKC that either cooperate or 
exert opposite effects on the process of apoptosis.31 
MAPK are activated by upstream MAP2K, which are, 
in turn, activated by MAP3K.31 Caspases are believed 
to be terminal executors of apoptosis, their activation 
mediated through cell death receptors. The NFkB is 
a  potential  prognostic  marker  capable  of  identify-
ing a high-risk subset of ER+, primary breast cancer 
destined for early relapse despite adjuvant endocrine 
therapy with tamoxifen.32 Additionally, initial studies 
have suggested that treatment strategies designed to 
prevent or interrupt activation of NFkB in cell line 
models of more aggressive ER+ breast cancers can 
restore their sensitivity to tamoxifen treatment.32 The 
P53 gene is a trascription factor that normally inhibits 
cell growth and stimulates cell death when induced 
by cellular stress.33,34 The most common way to dis-
rupt the P53 pathway is through a point mutation that 
inactivates its capacity to bind specifically to its cog-
nate recognition sequence.
We identified genes MSH2 and MSH6 involved in 
DNA repair and mismatch repair (MMR). Nuclear mis-
match repair has been initiated by the heterodimeric 
complexes hMSH2-hMSH6 (hMutSα) and hMSH2-
hMSH3  (hMutSβ).35  The  MSH2  gene    identified  in 
Figure 10. Pathways and gene regulatory networks for the signature of 54 genes, which exhibited significant differential expression. 
note: genes mapped to legend symbols in red contain SnPs and are upregulated. genes mapped to legend symbols in green contain SnPs and are 
down regulated. All other genes are predicted genes not reported in gWAS studies. Prediction based on genes associated with good and poor response 
to tamoxifen treatment.Response to tamoxifen treatment
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this  study  is  one  of  the  crucial  proteins  in  MMR. 
The response of the cell to DNA damage and its ability 
to maintain genomic stability by DNA repair are cru-
cial in preventing cancer initiation and   progression. 
Hence,  genetic  variants  of  DNA  repair  genes  may 
affect the process of carcinogenesis. Although the role 
of genetic variants mapped to DNA mismatch repairs 
genes in breast cancer is unknown, the importance of 
genetic  variability  of  the  components  of  mismatch 
repair genes is well documented in colorectal cancer.35 
In addition DNA repair genes are known to be sensi-
tive or responsive to changes in environment. Various 
DNA alterations can be caused by exposure to envi-
ronmental  and  endogeneous    carcinogenes.  Most  of 
these alterations if not repaired, can result in genetic 
instability,  mutagenesis  and  cell  death.    Ensuring 
fidelity of DNA replication is central to preserving 
genomic integrity, and DNA mismatch repair genes 
are critical for maintaining the fidelity of replication. 
The response of the cell to DNA damage and its ability 
to maintain genomic stability by DNA repair are cru-
cial in preventing cancer initiation and progression. 
Therefore, genetic variants in DNA repair genes may 
affect the process of carcinogenesis.
The results in this study provide proof-of-concept 
that  genes  and  pathways  containing  SNPs  associ-
ated with risk for breast cancer are dysregulated in 
response  to  tamoxifen  treatment.  Short  of  being 
able to sequence the entire genome of every tamox-
ifen  treated  patient  and  performing  allele-specific 
profiling,  how  does  one  rationally  go  about  iden-
tifying  genetic  polymorphisms  that  influence  drug 
response?. The results in this study demonstrate that 
integrating  GWAS  information  with  gene  expres-
sion data provides a holistic approach to identifying 
candidate genes and candidate pathways to make an 
informed prediction of the genes in which polymor-
phisms might affect the predisposition or response to 
tamoxifen treatment.   Additionally, the results show 
that  combining  GWAS  with  gene  expression  data 
can assist in the identification of as-yet-unrecognized 
potential drug targets.
Discussion
We describe an integrative genomics approach that 
combines  GWAS  information  with  gene  expres-
sion data to identify molecular signatures, biological 
pathways and gene regulatory networks, which are 
  dysregulated in response to tamoxifen treatment in 
ER+ breast cancer patients. Our work has the clini-
cal goal of better understanding the molecular mech-
anisms  underlying  variable  response  to  tamoxifen 
treatment  in  ER+  breast  cancer  patients.  Key  find-
ings from this study can be summarized as follows: 
(a) Genes   containing SNPs associated with risk for 
breast cancer are dysregulated in response to tamox-
ifen  treatment  and  could  distinguish  treated  from 
untreated breast cancer patients. (b) Within tamox-
ifen treated patients, genes containing SNPs associ-
ated with risk for breast cancer were able to stratify 
patients into two groups. This is an important find-
ing  in  that  it  could  guide  stratification  of  patients 
into poor and good responders a key step in guiding 
patient treatment at point of care. This finding could 
also allow identification of genes which contribute 
to variable response to tamoxifen treatment a major 
step  in  identifying  molecular  mechanisms  which 
may  contribute  to  patients’  resistance  to  treatment 
and guide personalized treatment. (c) Pathways and 
gene regulatory networks containing SNPs associated 
with risk for breast cancer were found to be dysregu-
lated in response to tamoxifen treatment. This is an 
important finding in that such candidate pathways if 
confirmed could be targeted for therapy. To the best 
of our knowledge such findings have not been previ-
ously reported in breast cancer.
Clearly, application of GWAS information in   clinical 
practice has been complicated by the fact that studies of 
risk alleles for breast cancer have shown that although 
GWAS  can  identify  novel  genes  that  contribute  to 
risk, the odds ratios and effect sizes as determined by 
P-values are relatively small.10,11 However, the results 
in this study demonstrate that genes containing SNPs 
with small P-values and SNPs replicated in multiple 
independent  studies  interact  with  genes  containing 
SNPs with moderate P-values in biological pathways 
which  influence  response  to  tamoxifen    treatment. 
This finding has two important   implications: first, it 
allows identification of potential candidate genes and 
candidate pathways that could serve as drug targets if 
  confirmed. Second, it demonstrates that genes contain-
ing SNPs with small P-values act in concert with those 
containing SNPs with moderate P-values. This is an 
important aspect of these results given that most of 
the loci found to date are small and replication in most 
GWAS studies tends to be elusive.hicks et al
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Currently,  few  clinically  relevant  genome-wide 
association studies of drug response phenotypes on 
breast  cancer  have  been  reported  that  it  is  impos-
sible  to  effectively  compare  our  results.  However, 
the results reported in this study are consistent with 
the 12 pharmacogenomics-based GWAS on various 
  diseases reported and summarized by Crowley et al.36 
The  main  difference  between  our  study  and  these 
studies is that rather than identifying polymorphisms 
altering drug response, our focus was on identify-
ing  genes  and  key  biological  pathways  containing 
SNPs, which are key drivers of response to tamox-
ifen treatment. The results demonstrate that integra-
tion  of  GWAS  information  with  gene  expression 
data on breast cancer patients uniformly treated with 
  tamoxifen is an essential tool to identifying genes and 
key  biological  pathways  in  which  polymorphisms 
might affect the disposition or response to tamoxifen 
treatment. Although this study focuses on tamoxifen, 
this  approach  could  be  applied  to  any  given  drug 
where GWAS information and gene expression are 
available.
The  results  in  this  study  show  that  response 
to  tamoxifen  involves  many  genes  and  multiple 
  pathways. These results are consistent with earlier 
reports based on expression profiling,6,8 and those 
reported recently by Mendes-Pereira et al.9   However, 
one caveat is important in this study. The results 
in this study do not show how individual SNPs or 
alleles contribute to variable response to tamoxifen 
treatment. This is a key limitation of this study and 
is acknowledge here. However, the results of this 
study provide a proof-of-concept and information 
about the biological pathways in which SNPs asso-
ciated with risk for breast cancer operate. The prac-
tical clinical utility of that type of information is that 
it could guide future experimental designs to identify 
candidate  genes  and  candidate  pathways  contain-
ing SNPs, which are key drivers of drug response 
and could be potential targets for therapy. In fact, 
although  we  did  not  investigate  allele-  specific 
expression or the effect of genetic variants on gene 
expression, previous studies have demonstrated that 
individual  alleles  could  affect  gene  expression  in 
humans.37,38 For example, a recent study showed that 
allele specific up-regulation of the FGFR2 (the most 
replicated gene in GWAS) increased susceptibility 
to breast cancer.39
The  potential  clinical  relevance  of  the  results 
reported in this study can be summarized as follows: 
(1). High-throughput SNP-mapping combined with 
transcription  profiling  could  potentially  allow  can-
cer associated drug targets to be identified thereby 
reducing attrition in early-phase clinical trials. For 
example, the cost of additional clinical trials might 
be reduced if the population of responders and non-
responders could be segmented on the basis of their 
genetic  profiles  in  early  phases  of  clinical  trials.40 
SNPs identified from candidate genes in early phases 
of clinical trials could allow non-responders to be 
excluded from subsequent clinical trial studies, there-
fore  potentially  allowing  enriched,  smaller,  faster, 
less expensive clinical studies on patients with better 
chance of responding favorably.40 (2) Although classic 
response to tamoxifen treatment has been assessed by 
polymorphisms in the CYP2D6 gene, the results from 
this study and others studies,6,8 show that response to 
tamoxifen treatments is under polygenic control. The 
identification of multiple pathways that are dysregu-
lated in response to tamoxifen treatment tends to sug-
gest that global pathway crosstalk may be involved. 
(3) The results show that integrative analysis com-
bining GWAS information with gene expression data 
could potentially identify candidate genes and poten-
tial drug targets that lie outside of the current range of 
knowledge. This approach could also potentially pro-
vide novel biological insights into the mechanisms of 
drug action and resistance. However, further studies 
will be required to determine how individual SNPs 
influence gene expression and response to tamoxifen 
treatment  before  firm  conclusions  of  the  practical 
utility of GWAS information in a clinical setting can 
be drawn. Such investigation though warranted, was 
beyond the scope of this report, but is the subject of 
our future studies.
Several studies from our own group10,11 and   others 
breast  cancer41,42  have  reported  pathway-based 
approaches to dissection of the genetic susceptibility 
architecture of breast cancer. To our knowledge, this 
is the first study to associate GWAS information with 
response to tamoxifen treatment and to identify genes 
and  biological  pathways  dysregulated  in  response 
to tamoxifen treatment. Recently, Genomic Health 
(Redwood City, CA) developed the Oncotype DX 
diagnostic assay based on candidate gene selection 
(not genome wide) approach.7 The   multiplex 21-gene Response to tamoxifen treatment
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test  includes  genes  associated  with    proliferation, 
estrogen, and HER2 action, invasion, and five con-
trol genes. This 21-gene recurrence score assay pro-
vides  a  recurrence  score  for  node-negative  breast 
cancer patients with ER+ tumors who have received 
adjuvant   tamoxifen.7 The association between this 
21-gene recurrence assay and risk of locoregional 
recurrence in node-negative estrogen receptor-posi-
tive breast cancer has been established using results 
from  NSABP  B-14  and  NSABP  B-20.43 The  util-
ity of the Oncotype DX risk estimates in clinically 
intermediate risk hormone receptor-positive, HER2-
  normal, grade II, lymph node-negative breast cancers 
has also be been established.44 Although our study 
was not designed to develop a therapeutic index or 
to evaluate the Oncotype DX assay, the findings are 
consistent with those reported in the Oncotype DX 
assay in that regulation and response to tamoxifen is 
under polygenic control. In fact, we indentified two 
genes ESR1 and ERBB2, which are also found in the 
Oncotype DX assay.
One of the major challenges in endocrine   therapy 
is  resistance  to  tamoxifen  treatment,  and  many 
patients who respond tend to relapse. In this study, 
71  patients  relapsed  out  of  the  298  treated  with 
tamoxifen, while the rest exhibited significant varia-
tion in response to tamoxifen. The genetic mecha-
nisms underlying resistance to tamoxifen treatment 
remain  poorly  understood.  Our  analysis  revealed 
that genes containing SNPs are co-regulated with 
genes  that  are  predictive  of  tamoxifen.  This  is  a 
significant finding given the urgent need to identify 
predictive markers and potential targets for devel-
oping novel therapeutic strategies. The association 
of tamoxifen resistant and SNP-containing genes is 
consistent  with  recent  studies.20,21  However,  more 
research is needed to ascertain the role of SNPs in 
tamoxifen treatment. Although such a study would 
provide more insights about the genetic mechanisms 
underlying variability and resistance to tamoxifen 
treatment, it is beyond the scope of this paper, but is 
the subject of our ongoing investigation and will be 
reported elsewhere.
The  results  reported  in  this  study  explain  the 
broader  context  in  which  genes  containing  SNPs 
associated  with  risk  for  breast  cancer  operate  in 
response to tamoxifen treatment. However, the limi-
tations of the study must be acknowledged. First, our 
study relies on use of publicly available data, which 
could  have  some  deficiencies,  such  as    sampling 
errors,  genetic  and  phenotypic  heterogeneity,  and 
environmental factors which were not corrected for. 
In  addition,  the  data  did  not  include  other  factors 
such as age, tumor grade, tumor size. Therefore, these 
results cannot be generalized and their interpretation 
should be conservative. Majority of the GWAS stud-
ies and gene expression data used in this study are 
based on Caucasian population. Given the emerging 
evidence that genetic susceptibility loci may confer 
population-specific  risk,45  and  the  plausibility  that 
response to tamoxifen could potentially differ between 
populations, these results cannot be generalized to all 
populations. Use of association results diagnostically 
will require explicit evaluation of how well they can 
be  transferred  across  different  population  groups. 
Additionally, further research is needed to determine 
the  effects  of  genetic  variants  on  gene  expression 
in different populations. One such approach would 
involve assessment of allelic variation in gene expres-
sion among breast cancer patients.31,39 Such analysis 
was beyond the scope of this report.
However, despite these limitations, the results from 
this study provide insights about the global biological 
context in which SNPs associated with risk for breast 
cancer operate in tamoxifen treated patients. This is 
a major step towards translating GWAS discoveries 
into clinical practice. The results of this study could 
guide future experimental designs in breast cancer to 
identify targets for the development of more effective 
therapeutic strategies.
In  conclusion,  our  data  shows  that  combining 
gene expression profiling with GWAS information 
provides a unified approach to identifying candidate 
genes  and  candidate  pathways  containing  SNPs, 
which  are  dysregulated  in  response  to  tamoxifen 
treatment  in  ER+  breast  cancer.  Furthermore,  our 
analysis demonstrates that genes containing SNPs act 
in concert with experimentally confirmed   tamoxifen 
resistant  genes  to  confer  resistance  to  tamoxifen. 
Additional studies are needed to determine how indi-
vidual or all polymorphisms collectively contribute 
to variability to endocrine therapy in different ethnic 
populations, and to determine whether these poly-
morphisms could serve as potential biomarkers for 
stratifying  breast  cancer  patients  to  individualized 
therapies.hicks et al
64  Breast Cancer: Basic and Clinical Research 2012:6
Acknowledgments
This research was supported by funding from UMMC 
Cancer Institute, to which the authors are gratefully 
thankful.
Disclosures
Author(s)  have  provided  signed  confirmations  to 
the publisher of their compliance with all applicable 
legal and ethical obligations in respect to declara-
tion of conflicts of interest, funding, authorship and 
  contributorship, and compliance with ethical require-
ments in respect to treatment of human and animal 
test subjects. If this article contains identifiable human 
subject(s) author(s) were required to supply signed 
patient consent prior to publication. Author(s) have 
confirmed that the published article is unique and not 
under consideration nor published by any other pub-
lication and that they have consent to reproduce any 
copyrighted material. The peer reviewers declared no 
conflicts of interest.
References
  1.  American Cancer Society. Breast cancer facts and figures 2010. Atlanta 
American Cancer Society. 2010.
  2.  Early breast cancer trials’ collaborative group (EBCTCG). Tamoxifen for 
early breast cancer: An overview of the randomized trials. Lancet. 1998;351: 
1451–67.
  3.  Ingle JN. Pharmacogenetics and pharmacogenomics of endocrine agents for 
breast cancer. Breast Cancer Res. 2008;10(Suppl 4):S17.
  4.  Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial 
evaluating tamoxifen in the treatment of patients with node-negative breast 
cancer who have extrogen-receptor-positive tumors. N Engl J Med. 1989; 
320:479–84.
  5.  Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, 
estrogen-receptor-positive  breast  cancer:  long-term  findings  from  the 
National surgical adjuvant breast and bowel project randomized clinical 
  trials. Lancet. 2004;364:858–68.
  6.  Jansen MPHM, Foekens JA, van Staveren IL, et al. Molecular classifica-
tion of tamoxifen-resistant breast carcinomas by gene expression profiling. 
J Clin Oncol. 2005;23:732–40.
  7.  Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of 
tamoxifen-treated, node-negative breast cancer. New Eng J Med. 2004;351: 
2817–26.
  8.  Symmans  WF,  Hatzis  C,  Sotiriou  C, Andre  F,  et  al.  Genomic  index  of 
  sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010;28: 
4111–9.
  9.  Mendes-Pereira AM,  Sims  D,  Dexter T,  et  al.  Genome-wide  functional 
screen identifies a compendium of genes affecting sensitivity to tamoxifen. 
Proc Natl Acad U S A. 2011.
  10.  Hicks C, Pannuti A, Miele L. Association of GWAS information with the 
Notch signaling pathway. Cancer Informatics. 2011.
  11.  Hicks C, Asfour R, Pannuti A, Miele L. An integrative genomics approach 
to biomarker discovery in breast cancer. Cancer Informatics. 2011.
  12.  Sotiriou C, Wirapati P, Loi S, et al. Gene expression   profiling in breast 
  cancer: Understanding the molecular basis of   histologic grade to improve 
prognosis. J Nat Cancer Inst. 2006;98:262–72.
  13.  Microarray Analysis Suite 5.0, Affymetrix Inc. Santa Clara, California.
  14.  Berger JA, Hautaniemi S, Jarvinen A-K, Edgren H, Mitra SK, Astola J. 
Optimized lowess   normalization parameter selection for DNA microarray 
data. BMC   Bioinformatics. 2004;5:194.
  15.  Benjamini Y, Hochberg Yosef. Controlling the false discovery rat: a practi-
cal and powerful approach to multiple testing. J Royal Stat Society. Series B 
Methodology. 1995;57(1):289–300.
  16.  Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and dis-
play of genome-wide expression patterns. Proc Nat Acad Sci U S A. 1998; 
95:14863–8.
  17.  Morrissey ER, Diaz-Uriarte R. Pomello II: Finding differentially expressed 
genes. Nucl Acids Res. 2009;37:W581–6.
  18.  Reich M, Liefeld T, Gould J, Lerner J, Tamayo P. GenePattern 2.0. Nature 
Genetics. 2006;38(5):500–1.
  19.  SAS statistical System. SAS Cary, NC.
  20.  Giamas G, Filipova A, Jacob J, et al. Kinome screening for regulators of 
the estrogen receptor identifies LMTK3 as new therapeutic target in breast 
cancer. Nature Med. 2011;17(6):715–9.
  21.  Maraqa L, Cummings M, Peter MB, et al. Carcinoembryonic antigen cell 
adhesion molecule 6 predicts breast cancer recurrence following adjuvant 
tamoxifen. Clin Cancer Res. 2008;14(13):4355–6.
  22.  Bostner J, Waltersson MA, Fornander T, et al. Amplification of CCND1 and 
PAK1 as predictors of recurrence and tamoxifen resistance in post meno-
pausal breast cancer. Oncogene. 2007;26:6997–7005.
  23.  Vendrell JA, Ghayad S, Ben-Larbi S, et al. A20/TNFAIP3, a new estrogen- 
regulated  gene  that  confers  tamoxifen  resistance  in  breast  cancer  cells. 
Oncogene. 2007;26:4656–67.
  24.  Shoman N, Klassen S, McFadden A, et al. Reduced PTEN expression predicts 
relapse in patients with breast cancer treated tamoxifen. Modern Pathology.   
2005;18:250–9.
  25.  Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by 
  oestrogen receptor-PAX2 determine response to tamoxifen. Nature. 2008; 
456:663–67.
  26.  Ingenuity System. Ingenuity Inc. California.
  27.  Gene Ontology Consortium. Creating the gene ontology resource: Design 
and implementation. Genome Res. 2001;11:1425–33.
  28.  Evans WE, Relling MV. Pharmacogenomics: translating functional genom-
ics into rational therapeutics. Science. 1999;286:487–91.
  29.  Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets 
and side effects. New Eng J Med. 2003;348:538–49.
  30.  Musgrove  EA,  Sergio  CM,  Loi  S,  Inman  CK,  Anderson  LR,  et  al. 
  Identification  of  functional  networks  of  estrogen-and  c-Myc-responsive 
genes  and  their  relationship  to  response  to  tamoxifen  therapy  in  breast 
  cancer.   PLoS one. 2008;3(8):e2987.
  31.  Mandlekar S, Kong A-NT. Mechanisms of tamoxifen-induced apoptosis. 
Apoptosis. 2001;6:469–77.
  32.  Zhou  Y,  Eppenberger-Castori  S,  Eppenberger  U,  Benz  CC.  The  NFkB 
pathway and endocrine-resistant breast cancer. Endocrine-Related Cancer. 
2005;12:S37–46.
  33.  Elledge RM, Green S, Howes L, Clark GM, et al. bcl-2, p53, and response 
to tamoxifen in estrogen receptor-positive metastatic breast cancer: A south-
west oncology group study. J Clin Oncol. 1997;15(5):1916–22.
  34.  Berns EMJJ, Klijn JGM, van Putten WLJ, et al. P53 protein accumulation 
predicts poor response to tamoxifen therapy of patients with recurrent breast 
cancer. J Clin Oncol. 1998;16(1):121–7.
  35.  Poplawski T, Zadrozny M, Kolacinska A, et al. Polymorphisms of the DNA 
mismatch repair gene HMSH2 in breast cancer occurence and progression. 
Breast Cancer Res Treatment. 2005;94:199–204.
  36.  Crowley JJ, Sullivan PF, McLeod HL. Pharmacogenomic of genome-wide 
association studies: lessons learned thus far. Pharmacogenomics. 2009;10(2): 
161–3.
  37.  Yan H, Yuan W, Velculescu VE, et al. Allelic variation in gene expression. 
Science. 2002;297:1143.
  38.  Buckland  PR.  Allele-specific  gene  expression  differences  in  humans. 
Human Mol Genet. 2004;13(2):R255–60.
  39.  Meyer KB, Maia A, O’Reilly M, et al. Allele-specific up-regulation of FGFR2 
increases susceptibility to breast cancer. PLoS Biology. 2008;6(5):e108.Response to tamoxifen treatment
Breast Cancer: Basic and Clinical Research 2012:6  65
  40.  Roses AD. Pharmacogenetics and drug development: the path to safer and 
more effective drugs. Nature Reviews Genetics. 2004;5:645–56.
  41.  Haiman  CA,  Hsu  C,  de  Bakker  PIW,  et  al.  Comprehensive  association 
testing of common genetic variation in DNA repair pathway genes in rela-
tionship with breast cancer risk in multiple populations. Hum Mol Genet. 
2008;17(6):825–34.
  42.  Menashe I, Maeder D, Garcia-Closas M, et al. Pathway analysis of breast 
cancer genome-wide association study highlights three pathways and one 
canonical signaling cascade. Cancer Res. 2010;7(11):4453–9.
  43.  Manounas EP, Tang G, Fisher B, et al. Association between the 21-gene 
recurrence score assay and risk of locoregional recurrence in node-negative, 
estrogen receptor-positive breast cancer: Results from NSABP B-14 and 
NSABP B-20. J Clin Oncol. 2010;28(10):1677–83.
  44.  Kelly CM, Krishnamurthy S, Bianchini G, et al. Utility of Oncotype DX 
risk  estimates  in  clinically  intermediate  risk  hormone  receptor-positive, 
HER2-normal, grade II, lymph node-negative breast cancers. Cancer. 2010; 
116(22):5161–7.
  45.  Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encod-
ing leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial 
infarction. Nat Genet. 2006;38:68–74.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
hicks et al
66  Breast Cancer: Basic and Clinical Research 2012:6
supplementary Tables
Table A. List and estimates of P-values for the test and validation data sets, and gO information for all the 110 of all the 110 
genes containing SnPs associated with risk for breast cancer, provided as supplementary material. estimates of P-values 
are based on comparing eR+ patients treated with tamoxifen to eR+ patients not treated with tamoxifen.
Table B. List and estimates of P-values and gO information for all the 95 genes containing SnPs associated with risk for 
breast cancer, provided as supplementary material. estimates of P-values are based on comparison within the 298 eR+ 
patients treated with tamoxifen only. This analysis was carried out on the 95 genes dysregulated in response to tamoxifen 
to identify a gene signature which stratified tamoxifen treated patients.
Table c. Supplementary data. estimates of P-values and false discovery rate for tamoxifen resistant genes (*) and genes 
containg highly significant SNPs and replicated in mutiple independent studies. Estimates based on comparing tamoxifen 
treated to controls.